FDA Misbranding Action Cannot Be Based On WLF-Compliant Dissemination
Executive Summary
FDA should not be allowed to pursue a misbranding action based solely on the dissemination of information that complies with the district court's injunction in the Washington Legal Foundation decision, WLF argued in its Nov. 8 appellate brief.